Pharmaceuticals Financial News

Granules India Ltd.(up 2.98 per cent), Biocon Ltd.(up 1.87 per cent), Gland Pharma Ltd.(up 1.38 per cent), Laurus Labs Ltd.(up 1.14 per cent) and Ipca Laboratories Ltd.(up 0.87 per cent) were among the top gainers.

₹582 crore, attracted bids for 11,89,06,826 shares compared to the 85,34,681 shares available, according to NSE data.The portion allocated for Retail Individual Investors (RIIs) experienced a subscription rate of 38.41 times, while the segment for non-institutional investors saw a 24.63 times subscription. The Qualified Institutional Buyers (QIBs) portion received a subscription of 35 percent.

domestic funds are able to effectively counter selling bouts by foreign portfolio investors (FPIs) as and when they occur. Will that continue in 2025? Would domestic funds be able to keep buying amid rising valuations and slowing retail investments as is visible from the trend in systematic investment plan (SIP) schemes?

Subscribe to enjoy similar stories. India’s external trade, navigating a phase of uncertainty owing to the European Union's new carbon tax on imports and slowing consumption in Europe, is set face further pressure. The US will likely seek lower tariffs in the coming year as President-elect Donald Trump, who has charged New Delhi with imposing high tariffs, assumes office in January.

department of pharmaceuticals (DoP) has reprimanded AbbVie Healthcare India for unethical marketing practices after a top panel found the company violated provisions of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) by sponsoring foreign vacations to Monaco and Paris for 30 doctors.

Subscribe to enjoy similar stories. India presently has more than a quarter trillion dollars of essential imports. These include crude oil, coal, edible unrefined oil, fertilizer, steel and copper.

Subscribe to enjoy similar stories. Over 650 million adults globally suffer from obesity, and this number is only expected to rise. Simultaneously, the market for weight-loss drugs is experiencing a revolutionary shift, driven by advances in treatments like Ozempic, Wegovy, and Zepbound—three drugs that are showing remarkable results in combating obesity.

Sumit Gupta, AVP-Research, Centrum Broking, says the government is providing a push towards manufacturing and R&D. Indian pharma has technical know-how. Now, the government wants to do technical ‘know-why’. Say Indian companies are currently doing CDMO manufacturing for MNC players. The government wants us to do R&D, build on some basically blockbuster drugs and then outsource that to some other countries. In one of your recent reports, you say that the government policies are expected to aid the long-term growth of the pharma space. The government is focusing on the R&D side, they are focusing on building and promoting bulk drug parks. How do you see the domestic companies benefit out of the same and amongst this whole sector, which particular segment is expected to benefit the most? Sumit Gupta: The government is focusing on promoting R&D and manufacturing in the pharmaceutical sector and these policies will be catering to or helping the overall sector for the medium to long term. So, the policies like bulk drug parks or the PLI for the pharma scheme or PLI for manufacturing critical APIs, drug intermediaries and KSMs or PLL for medtech. These are some of the sectors which are expected to benefit from government schemes.

productivity in India.

Shares of Dr. Reddy's Laboratories Ltd.(up 1.37 per cent), Divi's Laboratories Ltd.(up 0.45 per cent) and Glenmark Pharmaceuticals Ltd.(up 0.06 per cent) ended the day as top gainers in the pack.

Standard Glass Lining Technology, a manufacturer of specialized engineering equipment for the pharmaceutical and chemical industries, has secured Rs 40 crore through pre-IPO funding via private placement from Amansa Investments. As per the company’s public announcement on December 17, 2024, it issued 28,57,142 equity shares to Amansa Investments at a price of Rs 140 per share (including a premium of Rs 130), in consultation with the lead bankers.

Subscribe to enjoy similar stories. Mumbai: A stone’s throw away from a Pradhan Mantri Jan Aushadhi Kendra in suburban Mumbai stands another pharmacy, called ‘Mumbai Jan Aushadhi’. Its walls are lined with branded generics—copies of once-patented drugs that are now sold and marketed by pharma companies.

equity sale of Rs 500 crore and an offer for sale (OFS) of 21 lakh shares, will close on December 24. The offer is being made through the book-building process, wherein about 75% is reserved for qualified institutional buyers, 15% for non-institutional investors, and 10% for retail investors.

pharma companies and government officials will meet Tuesday to iron out issues regarding over the counter (OTC) drugs. «Appropriate use of OTC drugs improves accessibility and affordability for treatment and prevention of commonly occurring conditions.

Subscribe to enjoy similar stories. Switzerland has suspended the Most-Favoured-Nation (MFN) clause in its Double Taxation Avoidance Agreement (DTAA) with India, significantly altering the tax treatment of cross-border dividends. Beginning 1 January 2025, dividend payments from Swiss entities to Indian investors will be taxed at 10%, double the current 5%.

Aurobindo Pharma USA Inc, a subsidiary of Hyderabad-based drug maker, is recalling over 1 lakh bottles of Cinacalcet tablets in multiple strengths. The New Jersey-based firm is recalling the product due to «GMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit,» the US health regulator said. The company initiated the Class II recall on November 7 this year. Cinacalcet tablets are used to treat hyperparathyroidism.

Bank of Baroda. Notably, the growth in exports to the US was higher than aggregate exports until FY00. However, the global financial crisis in 2008 slowed down growth until FY10. Since then, the growth in exports to the US has consistently outpaced the overall export growth, underscoring the growing importance of the American market for Indian exports.

A Danish court has sentenced a British hedge fund trader to 12 years in prison in connection with what authorities say was a 9 billion kroner ($1.3 billion) tax fraud, Danish justice officials confirmed

were among the top gainers.

The Ohio Supreme Court has ruled that Ohio's product liability law prohibits counties from bringing public-nuisance claims against national pharmaceutical chains as they did as part of national opioid litigation